Journal
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 84, Issue 2, Pages 239-251Publisher
WILEY
DOI: 10.1111/bcp.13456
Keywords
Crohn's disease; glucocorticosteroids; inflammatory bowel disease; network meta-analysis; systematic review; ulcerative colitis
Categories
Funding
- Abbvie
- Amgen
- Biogaran
- Biogen
- Boerhinger-Ingelheim
- Bristol-Myers Squibb
- Celgene
- Celltrion
- Ferring
- Forward Pharma
- Genentech
- H.A.C. Pharma
- Hospira
- Index Pharmaceuticals
- Janssen
- Lycera
- Merck
- Lilly
- Mitsubishi
- Norgine
- Pfizer
- Pharmacosmos
- Pilege
- Samsung Bioepis
- Sandoz
- Takeda
- Therakos
- Tillots
- UCB Pharma
- Vifor
Ask authors/readers for more resources
AimsOral systemic corticosteroids have been used to induce remission in patients with active inflammatory bowel disease (IBD) for over 50years; however, the wide array of adverse events (AEs) associated with these drugs prompted the development of steroid compounds with targeted delivery and low systemic bioavailability. This study assessed corticosteroids' comparative harm using network meta-analysis. MethodsWe searched PubMed, Scopus, Embase, the Cochrane Library, clinical trial registries, regulatory authorities' websites and major conference proceedings, through March 2017. Randomized controlled trials that recruited adult IBD patients and compared oral systemic corticosteroids (prednisone/prednisolone) or compounds/formulations with low systemic bioavailability (budesonide, budesonide MMX, and beclomethasone dipropionate) with placebo, or against each other, were considered eligible for inclusion. Two reviewers independently extracted study data and outcomes, and rated each trial's risk-of-bias. ResultsWe identified and synthesized evidence from 31 trials including 5689 IBD patients. Budesonide MMX was associated with significantly fewer corticosteroid-related AEs than oral systemic corticosteroids [odds ratio (OR): 0.25, 95% confidence interval (CI): 0.13-0.49] and beclomethasone (OR: 0.35, 95% CI: 0.13-1.00), but not significantly fewer AEs than budesonide (OR: 0.64, 95% CI: 0.37-1.11); it performed equally good with placebo. By contrast, the occurrence of serious AEs, and treatment discontinuations due to AEs, did not differ between the comparator treatments. ConclusionsBudesonide MMX is associated with fewer corticosteroid-related AEs than its comparator steroid treatments for adult IBD patients. Further high-quality research is warranted to illuminate the steroid drugs' comparative safety profiles.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available